ibandronate IV
Selected indexed studies
- Ibandronate: A Review in Japanese Patients with Osteoporosis. (Drugs Aging, 2016) [PMID:26915075]
- Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. (Osteoporos Int, 2012) [PMID:21975558]
- Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. (Clin Ther, 2005) [PMID:16199254]
_Worker-drafted node — pending editorial review._
Connections
ibandronate IV is a side effect of
Sources
- Ibandronate: A Review in Japanese Patients with Osteoporosis. (2016) pubmed
- Intravenous ibandronate: in the treatment of osteoporosis. (2006) pubmed
- Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. (2012) pubmed
- Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. (2005) pubmed
- Bisphosphonate nephrotoxicity. (2008) pubmed
- Bisphosphonates. (2006) pubmed
- Ibandronate reduces skeletal morbidity in patients with breast cancer. (2004) pubmed
- Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review. (2008) pubmed
- Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. (2004) pubmed
- [Osteoporosis treatment]. (2007) pubmed